The Community Resource in Targeted Therapies
Driving Knowledge. Empowering Change. Optimizing Outcomes.
ONCAlert | Upfront Therapy for mRCC
Videos  >  

Characterization of Immune-Related Adverse Events of Ipilimumab Versus Placebo in mCRPC

Tomasz Beer, MD, FACP
Published Online:7:18 PM, Tue April 29, 2014
Tomasz Beer, MD, FACP, professor of medicine, deputy director of the Knight Cancer Institute, Oregon Health and Science University, characterizes the immune-related adverse events associated with ipilimumab in a phase III metastatic castration-resistant prostate cancer trial.

Clinical Pearls:
  • Ipilimumab is an immune modulator that works by breaking tolerance and stimulating the immune system so that it can recognize and attack the prostate cancer
  • Since ipilimumab is not specific to a cancer antigen, it causes side effects that are related to an overactive immune system
  • The analysis of the trial found that the side effect profile of ipilimumab in prostate cancer is similar to what was previously described in melanoma, where the drug is approved
  • Standard approaches to the management of these side effects are almost always effective
Copyright © TargetedOnc 2018 Intellisphere, LLC. All Rights Reserved.